Bluebird Bio是一家基因治疗公司,私募股权在金融斗争中以3 000万美元买下。 Bluebird Bio, a gene therapy firm, is bought by private equity for $30 million amid financial struggles.

Bluebird Bio是一家基因治疗公司,它同意由私人股权公司Carlyle和SK资本以约3 000万美元的价格购买。 Bluebird Bio, a gene therapy company, has agreed to be bought by private equity firms Carlyle and SK Capital for about $30 million. 股东每股将得到3美元,如果公司到2027年达到6亿美元的销售额,每股可能增加6.84美元。 Shareholders will receive $3 per share, with a potential additional $6.84 per share if the company reaches $600 million in sales by 2027. 蓝鸟的金融斗争和监管障碍导致了这一交易,目的是为该公司提供继续发展其疗法所需的资本。 Bluebird's financial struggles and regulatory hurdles led to the deal, which aims to provide the company with the capital needed to continue developing its therapies. 预计今年上半年这一收购将结束。 The acquisition is expected to close in the first half of this year.